Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 4, 2023

Advances in the study of the pathogenesis of cytokines in inflammatory bowel disease

Download as PDF

DOI: 10.23977/medsc.2023.040413 | Downloads: 18 | Views: 396

Author(s)

Qianqian Xiao 1, Yi Li 2, Yun Li 2, Juanni Zhao 2

Affiliation(s)

1 Shaanxi University of Traditional Chinese Medicine, Xianyang, 712000, China
2 Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, 712000, China

Corresponding Author

Yi Li

ABSTRACT

In recent years, with the continuous development of medical technology, people pay more and more attention to health. From a global perspective, the prevalence of inflammatory bowel disease (IBD) is increasing, and this disease is recurrent and persistent, and may bring physical and psychological harm to patients in the later stage, so the diagnosis and treatment of IBD and its prognostic effect become a clinical. This makes the management and prognosis of IBD a clinical challenge. The cause of IBD is still unclear, but as research continues, it is thought that the pathogenesis of IBD may be related to abnormal immune imbalances in the gut caused by environmental, genetic, immune and intestinal micro-ecological factors. Nowadays, research on the pathogenesis of IBD has been deepened and refined, and it has been found that there are more studies on immune factors and their conclusions are widely accepted, but the mechanisms of interleukin (IL) and tumour necrosis factor (TNF) are more widely studied. This article will mainly review the pathogenesis of IBD from the perspective of cytokines and provide reference for future clinical studies.

KEYWORDS

IBD, cytokines, interleukin (IL), tumour necrosis factor (TNF), review

CITE THIS PAPER

Qianqian Xiao, Yi Li, Yun Li, Juanni Zhao, Advances in the study of the pathogenesis of cytokines in inflammatory bowel disease. MEDS Clinical Medicine (2023) Vol. 4: 84-90. DOI: http://dx.doi.org/10.23977/medsc.2023.040413.

REFERENCES

[1] Malik TA. Inflammatory Bowel Disease: Historical Perspective, Epidemiology, and Risk Factors. Surg Clin North Am. 2015 Dec;95(6):1105-22, v. 
[2] He Q, Li JD. Advances in the epidemiology of inflammatory bowel disease[J]. Journal of practical medicine, 2019, 35(18):2962-2966.
[3] Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014 Jan 7;20(1):91-9. 
[4] Li XF, Peng X, Zhou MH. Advances in the epidemiology of inflammatory bowel disease in China[J]. Modern digestion and interventional diagnosis and treatment, 2020, 25(09):1265-1267. 
[5] Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013 Oct;76:1-8.
[6] Trenova AG, Slavov GS, Manova MG, Miteva LD, Stanilova SA. A Role of Cytokine Gene Polymorphisms in Cognitive Functioning. Folia Med (Plovdiv). 2018 Jun 1;60(2):191-199.
[7] Sun QJ, Li Q, Wan D, Lu SHR, Xu M, Zheng P. Analysis of cytokine expression in intestinal mucosa of patients with inflammatory bowel disease[J]. Gastroenterology, 2018, 23(01):13-17.
[8] Bregenholt S, ren. Cells and cytokines in the pathogenesis of inflammatory bowel disease: new insights from mouse T cell transfer models.[J].Experimental & Clinical Immunogenetics, 2000, 17(3):115-129.DOI:10.1159/000019131.
[9] Lu Y, Li X, Liu S, Zhang Y, Zhang D. Toll-like Receptors and Inflammatory Bowel Disease. Front Immunol. 2018 Jan 30;9:72. 
[10] Ahluwalia B, Moraes L. Magnusson MK, Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018 Apr;53(4 ):379-389. 
[11] Schreiber S, Raedler A, Stenson W F ,et al.The role of the mucosal immune system in inflammatory bowel disease.[J].Gastroenterology Clinics of North America, 1992, 21(2):451.DOI:10.1055/s-2007-1010517.
[12] Yan JB, Luo MM, Chen ZY, He BH. The Function and Role of the Th17/Treg Cell Balance in Inflammatory Bowel Disease. J Immunol Res. 2020 Dec 15;2020. 8813558. 
[13] Yan Y U, Guangming H .Advances in Study on Cytapheresis in Treatment of Inflammatory Bowel Disease[J].Chinese Journal of Gastroenterology, 2016.DOI:10.3969/j.issn.1008-7125.2016.12.014.
[14] Shi YQ, et al. "Correlation analysis of miRNA-10a expression with serum TNF-α and IL-6 levels in patients with inflammatory bowel disease in active and remission phases." Chinese Journal of Integrative Medicine and Digestion 30.08(2022):579-584. 
[15] Zhang Xianming, Yang Jinping. Expression and clinical significance of interleukin-13, interleukin-1 receptor antagonist and cyclooxygenase-2 in the serum of patients with inflammatory bowel disease[J]. China Pharmaceutical Science, 2021, 11(13):137-141.4443.  
[16] Li M.H., Zhang J. Progress of IL-36 in inflammatory bowel disease[J]. Journal of gastroenterology and hepatology, 2022, 31(09):1067-1070.  
[17] Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JGW. Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics. 2020 Jun 11;12(6):539.
[18] Hou Y, Lingxu LJ, Liu MODR. Advances in the study of cytokines in the pathogenesis of inflammatory bowel disease[J]. Hainan Medicine, 2023, 34(05):740-743.
[19] He C, Ye F, Zhang GX. The role of intestinal flora in anti-tumor necrosis factor-alpha biologics for inflammatory bowel disease[J]. Journal of Gastroenterology and Hepatology, 2021, 30(01):16-20. 
[20] Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014 Jan 7;20(1):91-9. 
[21] Singh N, Bernstein CN. Environmental risk factors for inflammatory bowel disease. United European Gastroenterol J. 2022 Dec;10(10):1047-1053
[22] Zhu Shanshan, Lin Mengyue, Chen Yamei. Advances in dietary management of patients with inflammatory bowel disease[J]. Modern Digestive and Interventional Medicine, 2021, 26(03):409-413.
[23] Mentella MC, Scaldaferri F, Pizzoferrato M, Gasbarrini A, Miggiano GAD. Nutrition, IBD and Gut Microbiota: A Review. Nutrients. 2020 Mar 29;12(4). 944. 
[24] Xu S F, Liang Z L, Zeng R Z, Lv X D, Liu G F, Lv S P. Association of PTGER4 gene polymorphism with inflammatory bowel disease in Zhuang and Han populations in Guangxi [J]. Journal of practical medicine, 2019, 35(10):1566-1570. 
[25] Kelsen JR, Sullivan KE. Inflammatory Bowel Disease in Primary Immunodeficiencies. Curr Allergy Asthma Rep. 2017 Aug;17(8):57.
[26] Li Y, Xiao QQ, Zhao JN, Li Y, Jia Y, Chen H. Research progress on the mechanisms related to intestinal flora and causing inflammatory bowel disease[J/OL]. Journal of Medical Research:1-5[2023-03-17].
[27] Xian-Min L. The Advance of Study on Th17 Cells and the Related Cytokines in Immunoregulatory of Inflammatory Bowel Disease[J].Chinese General Practice, 2011.DOI:10.1002/crat.201000663.
[28] Liu JW, Yin YQ. Research progress on the mechanism and treatment of intestinal flora dysbiosis associated with inflammatory bowel disease[J]. Chinese Journal of Geriatric Multiorgan Diseases, 2022, 21(05):397-400.
[29] Yang Wenhong, Sun Huifang, Qiu Fang. Expression of inflammatory factors combined with CD4 in patients with inflammatory bowel disease and the relationship with intestinal flora[J]. Chinese Experimental Diagnostics, 2021, 25(11):1674-1676.
[30] Lin T, Liu S, Ye YW, Zhang HL, Ren X, Lu H, Zhou YN. Research progress on the role of intestinal flora in the occurrence of extraintestinal manifestations of IBD[J]. Shandong Medicine, 2023, 63(01):80-84.  
[31] Li Sihui, and Wu Qiaofeng." Research progress on the influence of intestinal flora on Th17/Treg immune homeostasis and inflammatory bowel disease." Journal of Immunology 35.08 (2019):722-726.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4689
Visits: 204192

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.